For a biotechnology company, everything hinges on whether its treatments actually work in patients. Scancell (LSE:SCLP) is developing cancer immunotherapies designed to harness the immune system against tumours. Its lead melanoma programme has produced striking trial data. Understanding what convincing clinical evidence would mean for Scancell is central to grasping the potential – and the risks – of this developer.

A cancer-immunotherapy developer

Scancell Holdings, listed on London’s AIM, develops off-the-shelf cancer immunotherapies, often described as therapeutic cancer vaccines, designed to stimulate the immune system to attack tumours. It works across platforms including its DNA-based ImmunoBody technology, behind its lead melanoma candidate iSCIB1+, and its Moditope platform, behind Modi-1, being studied in solid tumours. It also has antibody work through GlyMab. As a clinical-stage biotech, Scancell has no product Revenue yet; its value rests on the promise of its pipeline and the clinical evidence supporting it.

Striking melanoma data

Scancell’s lead programme has generated notable results. In its SCOPE Phase 2 study of iSCIB1+ in advanced melanoma, it reported progression-free survival of about 77% at 20 months in the target patient population, a substantial improvement over the roughly 43% reported for a standard-of-care combination. The relevant patients carry certain HLA markers present in around 80% of melanoma cases. Further survival data are expected in 2027. Such figures, if confirmed, would represent a meaningful advance in a serious cancer.

Regulatory momentum

The data have attracted regulatory support. The US Food and Drug Administration granted iSCIB1+ Fast Track Designation in advanced melanoma, which can speed development and review and opens eligibility for Accelerated Approval pathways. Scancell also received clearance to proceed towards a registrational Phase 3 trial, with initiation anticipated in the second half of 2026. This progress reflects growing confidence in the programme and moves it closer to the large, definitive study needed to support potential approval, an important validation for the company.

Why the evidence is decisive

For Scancell, convincing clinical evidence is everything. Positive, statistically robust results from a large Phase 3 trial would be needed to gain approval and bring a product to market, transforming the company from a pre-revenue developer into one with a marketable therapy or a valuable asset to license or sell. Strong data can attract partners, funding and investor confidence; disappointing data can devastate a biotech’s value. The striking Phase 2 figures are encouraging, but only rigorous later-stage evidence can truly prove the therapy works.

The risks to weigh

The risks are those of clinical-stage biotech, and they are high. Many promising Phase 2 results Fail to be confirmed in larger Phase 3 trials, and Drug Development is long, costly and uncertain. Scancell has no product revenue and depends on funding, so it may need to raise capital, risking dilution. Trials can face delays, safety issues or regulatory setbacks. Reliance on its lead programme concentrates risk, and even successful drugs face commercial and competitive challenges. Investors should treat it as high-risk.

So what would convincing evidence mean?

Convincing clinical evidence, above all positive Phase 3 data, would mean Scancell could pursue approval for iSCIB1+, potentially transforming it into a company with a marketable cancer therapy and attracting partners, funding and investor confidence. The striking Phase 2 melanoma results, Fast Track status and Phase 3 progress are genuinely encouraging steps. But clinical, funding and regulatory risks are very high, and later trials can disappoint. Investors should watch trial results closely, as they will decide Scancell’s fate. Investors should watch the Phase 3 trial and forthcoming survival data as the clearest guides to whether the melanoma programme succeeds. Convincing late-stage evidence separates a marketable therapy from disappointment.